scholarly journals Programmed Death Ligand-1 (PD-L1) expression is up-regulated and related to the pattern of invasion in FIGO Stage I vulvar squamous cell carcinomas

2020 ◽  
Vol 10 (1) ◽  
pp. 4
Author(s):  
Hermann Brustmann
Keyword(s):  
Squamous Cell ◽  
Figo Stage ◽  
Squamous Cell Carcinomas ◽  
Stage I ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Pattern Of Invasion

scholarly journals Programmed Death Ligand 1 Expression in Laryngeal Squamous Cell Carcinomas and Prognosis

2020 ◽  
Vol 13 ◽  
pp. 2632010X2096484
Author(s):  
Sebnem Batur ◽  
Zeynep Ecem Kain ◽  
Emine Deniz Gozen ◽  
Nuray Kepil ◽  
Ovgu Aydin ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Squamous Cell ◽  
Immunohistochemical Staining ◽  
Squamous Cell Carcinomas ◽  
Immunohistochemical Expression ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Positive Score ◽  
Combined Positive Score ◽  
Membranous Staining

Aim: We aimed to show the immunohistochemical expression of programmed death ligand 1 (PD-L1) in laryngeal squamous cell carcinomas (SCCs). Materials and methods: The study includes 52 laryngeal SCC cases that underwent surgical resection. Immunohistochemical staining of PD-L1 (Clone 22C3) was applied to the sections obtained from paraffin blocks. Combined Positive Score (CPS) was evaluated as described in manuals. Tumor Proportion Score (TPS) was assessed by the percentage of positive tumor cells which were designated as positive if ⩾1% of the tumor cells showed membranous staining. Results: There were 35 cases (67.3%) having CPS < 1 and 17 cases (32.7%) having CPS ⩾ 1. There was no relationship between CPS, TPS, and the clinicopathological data. Conclusion: Further studies with a large number of advanced-stage cases are needed.

scholarly journals P37.34 Outcome Associations with p16, GATA-3, and TTF-1 Clone SP141 IHC Expression in Resected Stage I Lung Squamous Cell Carcinomas

2021 ◽  
Vol 16 (3) ◽  
pp. S456
Author(s):  
A. Shevtsov ◽  
I. Yambayev ◽  
K. Suzuki ◽  
T. Sullivan ◽  
K. Rieger-Christ ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Stage I ◽  
Resected Stage

Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab

2020 ◽  
pp. 107815522092260
Author(s):  
Abinav Baweja ◽  
Nataliya Mar
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papilloma Virus ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Penile Cancer ◽  
Checkpoint Inhibitors ◽  
Papilloma Virus ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Penile Squamous Cell Carcinoma

Introduction Prognosis for patients with lymph node positive or metastatic penile squamous cell carcinoma remains poor. Chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP regimen) is recommended as a first-line option in this cohort of patients. No standard preferred subsequent-line therapy exists for patients with relapsed or refractory penile carcinoma following TIP chemotherapy. Molecular pathogenesis of penile cancer can be subdivided into human papilloma virus-dependent and human papilloma virus-independent pathways. Recent studies have demonstrated increased expression of programmed death ligand-1 in some penile tumors, commonly those that are human papilloma virus-negative. Given the rarity of penile carcinoma in industrialized countries and lack of effective therapies, checkpoint inhibitors may be an attractive treatment option for this subset of patients. Case report We report a case of metastatic penile cancer refractory to TIP chemotherapy, with a dramatic treatment response to ipilimumab and nivolumab. Molecular profiling of this tumor showed a high programmed death ligand-1 expression, high tumor mutational burden, high microsatellite instability, and alterations in DNA mismatch repair genes. Discussion This case highlights another dimension of information that may be gained with molecular genomic profiling of penile tumors, providing insight into the biologic behavior of this neoplasm and assessing for predictive biomarkers of response to immune checkpoint inhibitors.

Abstract 4643: A novel 3-biomarker quantitative protein assay predicts survival in stage I lung squamous cell carcinomas

2010 ◽  
Author(s):  
Valsamo K. Anagnostou ◽  
Panagiota Kolokytha ◽  
Anastasios Dimou ◽  
Elizabeth J. Killiam ◽  
Vassiliki Zolota ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Stage I ◽  
Protein Assay

Clinical Significance of Programmed Death Ligand-1 Expression in Esophageal Squamous Cell Carcinoma

2020 ◽  
Vol 251 ◽  
pp. 321-328 ◽  
Author(s):  
Nozomi Ito ◽  
Hironori Tsujimoto ◽  
Hiroyuki Horiguchi ◽  
Hideyuki Shimazaki ◽  
Hiromi Miyazaki ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Significance ◽  
Squamous Cell ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

HIF expression and Max-SUV-18F-FDG-PET in non-small cell lung cancer (NSCLC) patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22010-e22010
Author(s):  
R. Lopez ◽  
E. Gallardo ◽  
A. Ruibal ◽  
L. Leon ◽  
A. Sanchez-Salmon ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Fdg Pet ◽  
Clinical Stage ◽  
Squamous Cell Carcinomas ◽  
Stage I ◽  
Immunohistochemical Expression ◽  
Small Cell Lung ◽  
Egfr Expression ◽  
18F Fdg ◽  
Nsclc Patients

e22010 Background: Tumor hipoxia induces the up-regulation of several genes via the hipoxia-inducible transcription factors (HIF) 1 and 2. HIF-2 alpha (HIF-2 α) and HIF-1 alpha (HIF-1α) are associated with the prognosis of operable NSCLC patients. We studied the immunohistochemical expression of HIF-1α and HIF-2 α in patients with NSCLC and the possible correlation with the maximum standardised uptake value (max SUV) of 18F-FDG as well as other biological parameters. Methods: We used a Tissue Arrayer device (Beecher Instruments. WI) to construct a TMA block, according to conventional protocols for the study of immunohistochemical expression of HIF-1α, HIF-2 α, EGFR, bcl-2, MIB1, p16, p63 and cyclins A, B1, D1 and D3. Sections were scored as positive if >10% of cells stained positively. Staining patterns were correlated to clinical variables. Results: HIF- 1α expression was observed in 84/96 patients (34/39 adenocarcinomas and 50/57 squamous cell carcinomas), however it did not correlate with clinical stage (I-II: 41/45 vs III-IV: 44/51). HIF-1α correlated positively with HIF-2 α (p:0,001) and EGFR (p:<0,001) expressions. The maxSUV values of 18F-FDG-PET were higher (p:0,039) in HIF-1α -positive (17,1±8,6) than in negative tumors (11,8±4,4). HIF-2 α expression was observed in 60/103 cases (27/42 adenocarcinomas and 33/61 squamous cell carcinomas) and it did not correlate with clinical stage ((I-II: 28/45 vs III-IV: 32/57). HIF-2 α correlated positively with HIF-1α (p:0,001), MIB1 (p:0,045) and EGFR (p:0,091) expressions. After multivariate analysis, only the clinical stage (RR: 2,2) was a prognostic factor. Conclusions: 1) HIF-1α and HIF-2 α expressions are frequent in patients with NSCLCs and it did not correlate with clinical stage; 2) maxSUVs FDG-PET values were higher in HIF1alpha positive than in HIF-1α negative patients; 3) HIF-1α was correlated with EGFR expression, while HIF-2 α was correlated with MIB1 expression. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document